By Fineline Cube CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a Phase II clinical trial of sirolimus (albumin-bound) for the treatment of patients with progressive or symptomatic epithelioid hemangioendothelioma (EHE). The novel intravenous formulation leverages proprietary albumin-binding technology to overcome limitations of oral sirolimus, enabling targeted delivery without corticosteroid premedication for this rare vascular tumor.
Clinical Development Milestone
| Component | Detail |
|---|---|
| Company | CSPC Pharmaceutical Group (HKG: 1093) |
| Product | Sirolimus for Injection (Albumin-Bound) |
| Trial Phase | Phase II |
| Indication | Progressive or symptomatic epithelioid hemangioendothelioma (EHE) |
| Classification | Class 2.2 improved new drug |
| Trial Design | Multi-center, open-label, non-randomized |
| Primary Endpoints | Efficacy and safety evaluation |
Product Innovation & Technology Platform
- Active Ingredient: Sirolimus (rapamycin), established mTOR inhibitor
- Delivery System: Proprietary human serum albumin encapsulation technology
- Key Advantages:
- Overcomes bioavailability limitations of oral formulations
- Achieves sufficient drug concentrations at target sites
- Eliminates need for corticosteroid premedication
- Enables intravenous administration with improved tolerability
- Regulatory Status: Classified as Class 2.2 improved new drug under China’s regulatory framework
- Intellectual Property: Protected by formulation and manufacturing process patents
Disease Background & Unmet Need
- Epithelioid Hemangioendothelioma (EHE): Ultra-rare vascular sarcoma with estimated incidence of 1 per 1 million population
- Clinical Challenge: Limited treatment options for progressive or symptomatic disease
- Surgical Limitations: Many patients are not candidates for curative surgery due to multifocal or metastatic disease
- Current Standard: No approved systemic therapies specifically for EHE; off-label use of various agents with limited efficacy
- mTOR Rationale: EHE frequently driven by WWTR1-CAMTA1 fusion leading to mTOR pathway activation
Trial Design & Patient Population
| Aspect | Details |
|---|---|
| Enrollment Criteria | Histologically confirmed progressive or symptomatic EHE |
| Surgical Status | Not candidates for curative surgery |
| Therapy Requirement | Require systemic therapy per investigator assessment |
| Study Sites | Multiple centers across China |
| Treatment Regimen | Intravenous albumin-bound sirolimus |
| Safety Monitoring | Comprehensive adverse event assessment and laboratory monitoring |
Strategic Implications & Pipeline Expansion
- mTOR Pathway Portfolio: Expands therapeutic applications of sirolimus beyond transplant immunosuppression
- Rare Disease Focus: Addresses significant unmet medical need in orphan oncology indication
- Platform Technology: Albumin-binding approach applicable to other poorly soluble compounds
- Regulatory Pathway: Class 2.2 designation may enable expedited review and approval process
- Commercial Potential: Orphan drug status could support premium pricing and market exclusivity
Market Context & Competitive Landscape
- Rare Sarcoma Market: Limited competition in EHE space with no approved targeted therapies
- mTOR Inhibitors: Established safety profile provides development advantage over novel mechanisms
- China Biopharma Innovation: Represents advanced formulation development capability among Chinese pharmaceutical companies
- Global Opportunity: Potential for international expansion following successful China development
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech